Get the Stockscreener App
495.42
1.45%
7.08
Pre-market:
494.05
-1.37
-0.28%
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Rating Upgraded by StockNews.com - Defense World
Vertex Pharmaceuticals (VRTX) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Vertex Pharmaceuticals EVP sells $1.62 million in stock - Investing.com
Vertex Pharmaceuticals EVP sells $1.6 million in stock - Investing.com
Vertex Pharmaceuticals Executives Sell Shares - TradingView
Vertex Pharmaceuticals CFO sells shares worth $1.65 million - Investing.com
Why Vertex Pharmaceuticals Incorporated (VRTX) is the Best Pharma Stock to Buy According to Hedge Funds - Insider Monkey
Should You Consider Adding Vertex Pharmaceuticals Incorporated (VRTX) to Your Portfolio? - MSN
Why Is Vertex (VRTX) Up 7.3% Since Last Earnings Report? - Yahoo Finance Australia
Where Will Vertex Pharmaceuticals Be in 10 Years? - sharewise
Vertex’s triple combination cystic fibrosis therapy Alyftrek approved by MHRA - PMLiVE
Rep. Jefferson Shreve Purchases Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - Defense World
If I Could Buy Only 1 Growth Stock, This Would Be It - The Motley Fool
UK MHRA approves Vertex’s Alyftrek for cystic fibrosis - Pharmaceutical Business Review
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Jones Financial Companies Lllp - Defense World
UnitedHealth slots Vertex's non-opioid pain med at top of tiered formulary - FirstWord Pharma
Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies - Benzinga
Vertex Pharmaceuticals (NasdaqGS:VRTX) Gains UK Approval For New Cystic Fibrosis Treatment - Yahoo Finance
Vertex Pharmaceuticals Says Journavx Non-Opioid Pain Killer Added to Optum Formulary - Marketscreener.com
Vertex Announces UK Mhra Approval Of Alyftrek -March 07, 2025 at 11:32 am EST - Marketscreener.com
Vertex Pharmaceuticals Gets UK Regulatory Approval for Alyftrek to Treat Cystic Fibrosis - Marketscreener.com
(Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis - Business Wire
Vertex Pharmaceuticals' Triple Combination Cystic Fibrosis Therapy Alyftrek Receives Approval in UK - Marketscreener.com
UK Health Regulator Approves Vertex's Cystic Fibrosis Drug Alyftrek -March 07, 2025 at 07:46 am EST - Marketscreener.com
Vertex Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Layoff Tracker: Atea Pharmaceuticals Cuts 25% of Workforce - BioSpace
Zacks Research Has Optimistic Outlook of VRTX Q1 Earnings - Defense World
Vertex Non-Opioid Pain Drug Draws Bipartisan Support In House Hearing - Citeline News & Insights
Vertex’s new pain drug gets first coverage nod from major insurer - BioPharma Dive
Insider Sell Alert: Ourania Tatsis Sells Shares of Vertex Pharma - GuruFocus.com
Vertex’s Non-Opioid Pain Drug Gets Some UnitedHealth Coverage - Bloomberg
Vertex’s non-opioid pain drug gets some UnitedHealth coverage - The Boston Globe
Vertex Pharma drops as UnitedHealth offers Tier 3 coverage for new pain medicine - MSN
Vertex Pharma stock drops on Journavx coverage (VRTX:NASDAQ) - Seeking Alpha
UnitedHealth includes Vertex’s non-opioid painkiller in coverage, but at a higher costBloomberg - Investing.com UK
Vertex Pharmaceuticals Incorporated to Host Earnings Call - ACCESS Newswire
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating - Seeking Alpha
Best Biotech Stocks to Buy in 2025 - The Motley Fool
Vertex Pharmaceuticals Stock: Is VRTX Outperforming the Healthcare Sector? - Nasdaq
Vertex Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch
Vertex Pharmaceuticals Stock: Is VRTX Outperforming The Healthcare Sector? - Barchart
Signs of hiring at Boston-area life sciences companies - The Business Journals
Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations - BioSpace
Vertex's cystic fibrosis combination therapy Symdeko gains FDA approval - FirstWord Pharma
Insider Sell: Ourania Tatsis Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus.com
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Acima Private Wealth LLC - MarketBeat
FourThought Financial Partners LLC Takes $279,000 Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Mutual of America Capital Management LLC Has $13.25 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Flputnam Investment Management Co. Purchases 22,141 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
QRG Capital Management Inc. Decreases Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Illinois Municipal Retirement Fund Has $19.08 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Longbow Finance SA Raises Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Y Intercept Hong Kong Ltd Makes New Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
ARK Investment Management LLC Sells 25,749 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
National Pension Service Increases Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
582 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Acquired by World Equity Group Inc. - MarketBeat
Vertex Pharmaceuticals EVP Tatsis sells $251,930 in stock - Investing.com
Vertex Pharmaceuticals' EVP sells $1.26m in stock - Investing.com
Vertex Pharmaceuticals’ EVP sells $1.26m in stock - Investing.com India
Vertex Pharmaceuticals exec sells $610,560 in stock - Investing.com India
3.99%
1.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):